L. Allegra (Milano, Italy), C. Page (London, United Kingdom)
Formoterol enhances glucocorticoid receptor nuclear translocation in steroid-insensitive severe asthma
K. Ito, M. Deguchi, I. M. Adcock, P. J. Barnes (London, United Kingdom)
|  |
Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma
E. Pace, R. Gagliardo, M. R. Melis, S. La Grutta, M. Ferraro, L. Siena, G. Bonsignore, M. Gjomarkaj, J. Bousquet, A. M. Vignola (Palermo, Italy; Montpellier, France)
| |
TGFβ-induced proteoglycan production and α-smooth muscle actin expression in cultured human lung fibroblasts is inhibited by combination of budesonide and formoterol
E. Gürcan, L. Todorova, A. Miller-Larsson, G. Westergren-Thorsson (Lund, Sweden)
| |
Beta2-agonists but not glucocorticoids inhibit proliferation of asthmatic airway smooth muscle cells
M. Roth, P. R. A. Johnson, J. K. Burgess, M. Tamm, J. L. Black (Sydney, Australia; Basel, Switzerland)
| |
Single inhaler therapy with budesonide/formoterol in an allergic rat model: a new therapeutic strategy in asthma
C. Brange, A. Smailagic, C. Eriksson, X. D. Wang (Lund, Sweden)
|  |
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide
R. H. Green, C. E. Ruse, A. P. Wheatley, I. P. Hall, I. D. Pavord (Leicester, Nottingham, United Kingdom)
| |
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
M. Ni Chroinin, I. Greenstone, P. G. Gibson, F. Ducharme (Montreal, Canada; Newcastle, Australia)
| |
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD)
M. Cazzola, A. Salzillo, P. Noschese, C. De Giglio, G. D‘Amato (Naples, Italy)
| |